Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus

Mohamad, W. B. Wan; Fizi, A Tun; Ismail, Rusli; Mafauzy, M

doi:10.1016/s0168-8227(00)00138-8

Cited by 22 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The considerable use of twice daily glibenclamide regimen (69%) in our study setting appear to have contributed to the high frequency of occurrence of hypoglycemia; as multiple dosing with glibenclamide has been shown to be a strong predictor [28,29]. However, the incidence of hypoglycemia could be reduced with the use of single daily dosing of glibenclamide which has been reported to be therapeutically equivalent to multiple daily regimens, and have the added benefits of improving patient adherence [30]. Furthermore, low-dose fixed combination of glibenclamide and metformin, which improves adherence, reduce pill burden and improve glycemic control was not prescribed for any of the cohort [31,32].…”

Section: Phase 1: Cross-section Review Of Patients' Case Notesmentioning

confidence: 94%

Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

2008

View full text Add to dashboard Cite

Majority of patients with type 2 diabetes in an ambulatory tertiary care setting in Nigeria are managed with OHA combinations, mainly glibenclamide and metformin. While the current prescribing strategy achieved glycemic control in about one third of patients, majority are still not meeting the recommended blood glucose targets due to poor adherence with prescribed drug regimen, and poor knowledge and practice of successful self-management.

show abstract

Section: Phase 1: Cross-section Review Of Patients' Case Notesmentioning

confidence: 94%

Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

2008

View full text Add to dashboard Cite

show abstract

“…Pharmaceutical agents that open or close K ATP channels have important clinical applications. K ATP channel openers, for example, diazoxide and nicorandil, are used to treat acute hypertension and angina , whereas the K ATP channel closer, glibenclamide, is used to treat type 2 diabetes . K ATP channels are prominently involved in the regulation of insulin secretion, cardioprotection and cellular adaptation to stress (shear, stretch, pressure and oxidation) and improve the overall cell well‐being .…”

mentioning

confidence: 99%

Cardioprotective Effects of Nicorandil, a Mitochondrial Potassium Channel Opener against Doxorubicin‐Induced Cardiotoxicity in Rats

Abdel-Raheem

Taye

Abouzied

2013

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Doxorubicin is a chemotherapeutic drug used to treat solid and haematopoietic tumours. Its use is limited by a major side effect of cardiotoxicity. It was reported that doxorubicin-induced cardiotoxicity is mediated through oxidative stress coupled with impaired NO bioavailability and NF-jB activation. Nicorandil, a mitochondrial ATP-dependent potassium (K ATP ) channel opener, was reported to be cardioprotective on ischaemic myocardium. However, the effect of nicorandil against doxorubicininduced cardiotoxicity has not yet been clarified. Accordingly, six groups of rats were used. The first three groups were injected with vehicle, nicorandil (3 mg/kg) orally and doxorubicin (a single intraperitoneal injection of 20 mg/kg), respectively. Group four was treated with nicorandil, whereas group five was treated with glibenclamide and then nicorandil starting 2 days before doxorubicin and continued for five consecutive days. Group six was treated with glibenclamide alone. At the end of the experiment, the rats were killed. Cardiac enzyme indexes were measured in serum. Heart tissues were processed for determination of nitrite/nitrate, NF-jB protein expression, glutathione (GSH), lipid peroxide (TBARS) levels and superoxide production. In addition to body-weight reduction, doxorubicin produced cardiotoxicity as indicated from the increase in lactate dehydrogenase (LDH), creatine kinase (CK) activities, TBARS, superoxide production, NF-jB expression and caspase-3 activity. Moreover, doxorubicin decreased GSH and nitrite/nitrate levels. Histopathological examination of doxorubicin-treated hearts revealed degenerative changes. On the other hand, nicorandil protected cardiac tissues against doxorubicin cardiotoxicity as demonstrated from normalization of cardiac biochemical and oxidative stress parameters and amelioration of histopathological changes. Glibenclamide, a blocker of the K ATP channel, reversed most of the cardiac effects of nicorandil.

show abstract

“…Sitagliptin 50 mg qd was chosen as the relevant dose for use in the study because it is the usual initial dose in Japan. For glibenclamide, a 1.25 mg bid dosing regimen was chosen because a daily dose of glibenclamide at 1.25–2.5 mg is the usual initial dose in Japan, and because, considering the pharmacokinetic/pharmacodynamic profile of glibenclamide, the bid dosing regimen was expected to achieve sustained drug exposure. Sitagliptin 50 mg was administrated once daily before breakfast, and glibenclamide 1.25 mg was administrated once before breakfast and once before dinner, except on Day 14.…”

Section: Methodsmentioning

confidence: 99%

Effect of short‐term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug‐naïve Japanese patients with type 2 diabetes mellitus

Suzuki

Eiki

Moritoyo

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus

Cited by 22 publications

References 11 publications

Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

Cardioprotective Effects of Nicorandil, a Mitochondrial Potassium Channel Opener against Doxorubicin‐Induced Cardiotoxicity in Rats

Effect of short‐term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug‐naïve Japanese patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About